Interfering with RAS-effector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth

Oncogene

Volumn 29, Issue 45, 2010, Pages 6064-6070

  Tanaka, T ^a   Rabbitts, T H ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

antibody fragment; cancer; lung tumourigenesis; RAS signalling; therapy

Indexed keywords

CELL ANTIBODY; DOXYCYCLINE; INTRACELLULAR DOMAIN ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; RAF PROTEIN; RAS PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CLARA CELL; CONTROLLED STUDY; EFFECTOR CELL; GENE MUTATION; LUNG CANCER; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REGRESSION;

3T3 CELLS; ANIMALS; CELL LINE, TUMOR; HUMANS; LUNG NEOPLASMS; MICE; MICE, TRANSGENIC; MUTATION; NEOPLASMS; RAS PROTEINS; SIGNAL TRANSDUCTION;

MUS MUSCULUS;

EID: 78149469676     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.346     Document Type: Article

References (27)

1. Brummelkamp TR, Bernards R, Agami R. (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247.
2. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N et al. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400: 468-472.
3. Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M. (2007). A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 21: 379-384.
4. Downward J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
5. Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM et al. (2010). Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. EMBO J 29: 1091-1104.
6. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ et al. (2001). Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15: 3249-3262.
7. Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A et al. (2006). Cosmic 2005. Br J Cancer 94: 318-322.
8. Gatenby RA. (2009). A change of strategy in the war on cancer. Nature 459: 508-509.
9. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B et al. (2007). Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
10. Herrmann C. (2003). Ras-effector interactions: after one decade. Curr Opin Struct Biol 13: 122-129.
11. Ikediobi ON, Davies H, Bignell G, Edkins S, Stevens C, O'Meara S et al. (2006). Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5: 2606-2612.
12. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA et al. (2001). Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410: 1111-1116.
13. Karnoub AE, Weinberg RA. (2008). Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 9: 517-531.
14. Kim CF, Jackson EL, Woolfenden AE, Lawrence S, Babar I, Vogel S et al. (2005). Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 121: 823-835.
15. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. (2001). Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20: 6551-6558.
16. Nassar N, Horn G, Herrmann C, Scherer A, McCormick F, Wittinghofer A. (1995). The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 375: 554-560.
17. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L et al. (1998). Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95: 3609-3614.
18. Pacold ME, Suire S, Perisic O, Lara-Gonzalez S, Davis CT, Walker EH et al. (2000). Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103: 931-943.
19. Plattner R, Anderson MJ, Sato KY, Fasching CL, Der CJ, Stanbridge EJ. (1996). Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci USA 93: 6665-6670.
20. Sharma SV, Settleman J. (2007). Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231.
21. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. (1993). Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88.
22. Soriano P. (1999). Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet 21: 70-71.
23. Tanaka T, Williams RL, Rabbitts TH. (2007). Tumour prevention by a single antibody domain inhibiting binding of signal transduction molecules to activated RAS. EMBO J 26: 3250-3259.
24. Vetter IR, Wittinghofer A. (2001). The guanine nucleotide-binding switch in three dimensions. Science 294: 1299-1304.
25. Weinstein IB. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
26. Weinstein IB, Joe A. (2008). Oncogene addiction. Cancer Res 68: 3077-3080.
27. Weir B, Zhao X, Meyerson M. (2004). Somatic alterations in the human cancer genome. Cancer Cell 6: 433-438.